JP6453243B2 - ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 - Google Patents

ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 Download PDF

Info

Publication number
JP6453243B2
JP6453243B2 JP2015555429A JP2015555429A JP6453243B2 JP 6453243 B2 JP6453243 B2 JP 6453243B2 JP 2015555429 A JP2015555429 A JP 2015555429A JP 2015555429 A JP2015555429 A JP 2015555429A JP 6453243 B2 JP6453243 B2 JP 6453243B2
Authority
JP
Japan
Prior art keywords
cbs
rhcbsδc
isolated
polypeptide
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015555429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506727A (ja
JP2016506727A5 (OSRAM
Inventor
ジャン ピー． クラウス，
ジャン ピー． クラウス，
トーマス マジタン，
トーマス マジタン，
エレス バブリル，
エレス バブリル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2016506727A publication Critical patent/JP2016506727A/ja
Publication of JP2016506727A5 publication Critical patent/JP2016506727A5/ja
Application granted granted Critical
Publication of JP6453243B2 publication Critical patent/JP6453243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
JP2015555429A 2013-01-29 2014-01-29 ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 Active JP6453243B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361758138P 2013-01-29 2013-01-29
US61/758,138 2013-01-29
US13/803,804 2013-03-14
US13/803,804 US9034318B2 (en) 2011-08-30 2013-03-14 Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
PCT/US2014/013602 WO2014120770A1 (en) 2013-01-29 2014-01-29 Cystathionine beta-synthase enzyme for treatment of homocystinuria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018232350A Division JP2019059768A (ja) 2013-01-29 2018-12-12 ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素

Publications (3)

Publication Number Publication Date
JP2016506727A JP2016506727A (ja) 2016-03-07
JP2016506727A5 JP2016506727A5 (OSRAM) 2017-04-13
JP6453243B2 true JP6453243B2 (ja) 2019-01-16

Family

ID=51223166

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015555429A Active JP6453243B2 (ja) 2013-01-29 2014-01-29 ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
JP2018232350A Withdrawn JP2019059768A (ja) 2013-01-29 2018-12-12 ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
JP2020169596A Active JP7240743B2 (ja) 2013-01-29 2020-10-07 ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素
JP2023028266A Active JP7580822B2 (ja) 2013-01-29 2023-02-27 ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018232350A Withdrawn JP2019059768A (ja) 2013-01-29 2018-12-12 ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
JP2020169596A Active JP7240743B2 (ja) 2013-01-29 2020-10-07 ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素
JP2023028266A Active JP7580822B2 (ja) 2013-01-29 2023-02-27 ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素

Country Status (13)

Country Link
US (4) US9034318B2 (OSRAM)
EP (4) EP3282013B1 (OSRAM)
JP (4) JP6453243B2 (OSRAM)
CN (2) CN105452457A (OSRAM)
AU (3) AU2014212471B2 (OSRAM)
BR (1) BR112015017775A2 (OSRAM)
CA (1) CA2898772A1 (OSRAM)
DK (1) DK3712264T5 (OSRAM)
FI (1) FI3712264T3 (OSRAM)
HK (1) HK1213291A1 (OSRAM)
IL (1) IL239783B (OSRAM)
PT (1) PT3712264T (OSRAM)
WO (1) WO2014120770A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019059768A (ja) * 2013-01-29 2019-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
US10653755B2 (en) 2013-01-29 2020-05-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11077175B2 (en) 2015-11-09 2021-08-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11324811B2 (en) 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251550A1 (en) 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
US11033612B2 (en) * 2017-05-12 2021-06-15 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
CN108795913B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物中能催化h2s产生的酶及其应用
AR116866A1 (es) 2018-10-26 2021-06-23 Univ Texas Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética
FI3990005T3 (fi) 2019-06-26 2025-11-28 Travere Therapeutics Switzerland Gmbh Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi
CN114630673A (zh) * 2019-09-03 2022-06-14 特拉维尔治疗瑞士有限公司 用于治疗升高的同型半胱氨酸水平的胱硫醚β-合成酶酶疗法
USD1013704S1 (en) * 2021-07-09 2024-02-06 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
USD1014518S1 (en) * 2021-07-09 2024-02-13 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
CN115721735A (zh) * 2022-10-13 2023-03-03 呈诺再生医学科技(北京)有限公司 Cbs基因在制备糖尿病视网膜病变治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209206A (en) 1981-06-08 1982-12-22 Kanebo Ltd Skin type pack agent
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6635438B2 (en) * 1999-11-02 2003-10-21 Catch, Inc. Enzymatic cycling assays for homocysteine and cystathionine
AU2003251550A1 (en) * 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN101322840A (zh) * 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
BR112013000027A2 (pt) 2010-07-01 2017-07-11 Isis Innovation tratamento de distúrbios cognitivos
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) * 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019059768A (ja) * 2013-01-29 2019-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
US10624959B2 (en) 2013-01-29 2020-04-21 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US10653755B2 (en) 2013-01-29 2020-05-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11400143B2 (en) 2013-01-29 2022-08-02 The Regents Of The University Of Colorado Compositions and methods for treatment of homocystinuria
US11077175B2 (en) 2015-11-09 2021-08-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US12194082B2 (en) 2015-11-09 2025-01-14 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11324811B2 (en) 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
US12042529B2 (en) 2017-04-17 2024-07-23 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria

Also Published As

Publication number Publication date
IL239783A0 (en) 2015-08-31
JP2021000142A (ja) 2021-01-07
US9034318B2 (en) 2015-05-19
AU2014212471A8 (en) 2015-08-13
US20150344864A1 (en) 2015-12-03
IL239783B (en) 2019-10-31
HK1249137A1 (en) 2018-10-26
FI3712264T3 (fi) 2024-05-07
JP2023062201A (ja) 2023-05-02
JP2016506727A (ja) 2016-03-07
EP4406536A3 (en) 2025-01-01
AU2014212471A1 (en) 2015-07-23
CN112574982B (zh) 2025-05-13
CA2898772A1 (en) 2014-08-07
CN105452457A (zh) 2016-03-30
JP7240743B2 (ja) 2023-03-16
EP4406536A2 (en) 2024-07-31
EP3712264A8 (en) 2020-11-04
AU2020200719A1 (en) 2020-02-20
EP2951299A1 (en) 2015-12-09
US20140212403A1 (en) 2014-07-31
US20170065687A1 (en) 2017-03-09
EP3712264A1 (en) 2020-09-23
DK3712264T5 (da) 2024-08-26
US9447406B2 (en) 2016-09-20
AU2014212471B2 (en) 2019-11-28
JP7580822B2 (ja) 2024-11-12
AU2022263598B2 (en) 2025-06-05
US10046036B2 (en) 2018-08-14
EP2951299B1 (en) 2017-07-12
US20180311325A1 (en) 2018-11-01
HK1213291A1 (zh) 2016-06-30
WO2014120770A1 (en) 2014-08-07
CN112574982A (zh) 2021-03-30
JP2019059768A (ja) 2019-04-18
EP3712264B1 (en) 2024-04-10
PT3712264T (pt) 2024-05-09
DK3712264T3 (da) 2024-05-06
BR112015017775A2 (pt) 2017-11-21
US10624959B2 (en) 2020-04-21
AU2022263598A1 (en) 2022-12-15
EP3282013A1 (en) 2018-02-14
EP3282013B1 (en) 2020-05-20
AU2020200719B2 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7580822B2 (ja) ホモシスチン尿症を処置するためのシスタチオニンβ－シンターゼ酵素
JP6704358B2 (ja) 代謝障害を治療するための組成物および使用方法
KR102811896B1 (ko) 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
ES2994256T3 (en) Compositions and methods for treatment of homocystinuria
JP2020519278A (ja) 高ホモシステイン血症およびホモシスチン尿症の患者を処置するための、ヒト酵素介在性のホモシステイン枯渇
HK40041316A (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
HK40041316B (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
HK1249137B (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
JP2025111469A (ja) シスタチオニン－ガンマ－リアーゼを使用するホモシスチン尿症及び高ホモシステイン血症の治療
KR20210084539A (ko) 치료학적 용도를 위한 조작된 영장류 시스틴/시스테인 분해 효소
BR112017001789B1 (pt) Polipeptídeos, dímero, método de produção dos mesmos, composição farmacêutica, uso dos mesmos e recipiente estéril para tratamento de distúrbios metabólicos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181212

R150 Certificate of patent or registration of utility model

Ref document number: 6453243

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250